Associated vaccine for prevention of anthrax and necrobacillosis in animals |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
IPC classes for russian patent Associated vaccine for prevention of anthrax and necrobacillosis in animals (RU 2480237):
 Multiple vaccination including serogroup c meningococci / 2457858
Group of inventions refers to medicine, and concerns multiple vaccination including serogroup C meningococci. Substance of the group of inventions involves an immunisation kit containing a first immunogenic component representing a conjugated capsular saccharide of the strain OAc+ Neisseria meningitides serogroup C and a lyophilised conjugated antigen Hib, and a second immunogenic component containing an aqueous formulation of diphtheria toxoid, tetanus toxoid and cell-free antigen B. pertussis. The invention also involves the application of the lyophilised capsular saccharide of the strain OAc+ Neisseria meningitides serogroup C conjugated with the carrier-protein tetanus toxoid and the aqueous cell-free antigen B. pertussis, for preparing an immunisation drug.
 Saccharide conjugated vaccines / 2454244
Invention discloses compositions for inducing an immune response in a patient, containing a combination of two or more monovalent conjugates wherein each of the monovalent conjugates contains a carrier protein N19 conjugated with a saccharide antigen of the serogroups A, C, W135 or Y Neissera meningitides. A molecule of the carrier protein in the monovalent conjugate is preferred to be conjugated with more than one molecule of the saccharide antigen. Besides, the invention discloses a multivalent conjugate for inducing an immune response in a patient, containing two or more antigen-different saccharide antigens of the serogroups A, C, W135 or Y Neissera meningitides conjugated with the carrier protein N19. The compositions may contain one or more said monovalent conjugates and one or more said multivalent conjugates. The invention shows applicability of the multivalent conjugate and compositions in preparing a medicine for enhancing the immune response in a patient.
 Immunogenic compositions containing lawsonia intracellulars / 2443430
Group of inventions refers to veterinary immunology. A combined vaccine of i) an avirulent isolate of Lawsonia intracellularis and ii) attenuated bacteria of Salmonella spp. effective for treating and/or preventing an infection caused by Salmonella spp., and iii) attenuated bacteria of Erysipelothrix rhsiopathiae effective for treating and/or preventing an infection caused by Erysipelothrix rhsiopathiae with such combined vaccine to be introduced in an animal which is other than a human for treating, preventing an infection and/or for relieving clinical symptoms caused by Salmonella spp. and Erysipelothrix rhsiopathiae Kits containing said immunological agents in one or more containers.
 Combined vaccines with low-dose hib conjugate / 2435609
Invention refers to medicine, and concerns combined vaccines with a low-dose HIB conjugate. The substance of the invention includes the combined vaccines containing diphtheria, tetanus, whooping cough and HIB immunisation antigens (DTP-HIB vaccines), in which: (a) Hib protection antigen represents a capsular saccharide Hib conjugate; (b) the concentration of Hib conjugate in the vaccine makes 1.25 to less than 15 mcg/ml; and (c) Hib conjugate is never lyophilised.
 Method of manufacturing associated vaccine against colibacteriosis, streptococcosis and enterococcal infection of calves and piglets / 2429012
From affected organs of calves and piglets isolated are epizootic strains of Escherichia coli, producing thermally labial, thermally stable and Shiga-like toxins, as well as of hemolytic strains of Streptococcus bovis and Enterococcus faecalis. Cultures of Escherichia coli, Streptococcus bovis and Enterococcus faecalis are separately grown on nutrient broth at temperature 37°C. Cultures of Escherichia coli are grown for 7 days and cultures of Streptococcus bovis and Enterococcus faecalis for 24 hours until concentration of 5-6 billion microbial bodies in 1 ml is achieved. After that grown cultures are separately inactivated with formalin to concentration of 0.3-0.4% during 14 days. After that cultures are mixed in equal volume, packed and sealed.
Associated vaccine against anaerobic enterotoxemia and colibacillosis diarrhea in calves / 2428202
Invention refers to veterinary microbiology. The vaccine contains the following components related to 1 l of the vaccine: suspension of No. 28 Cl.perfringens type A strain cells in a culture medium in the concentration 3.5·1012-4.0·1012, cm3 - 140.0-160.0; suspension of No.392 Cl.perfringens type C strain cells in a culture medium in the concentration 3.5·1012-4.0-1012, cm3 - 140.0-160.0; suspension of No.213 Cl.perfringens type D strain cells in a culture medium in the concentration 3.5·1012-4.0·1012, cm3 - 140.0-160.0; suspension of E.coli KB-1 strain cells containing adhesive antigen K99 in physiologic saline in the concentration 100·1012-120·1012, cm3 - 25.0-30.0, suspension of E.coli "ПЗ-3" strain cells containing adhesive antigen A20 in physiologic saline in the concentration 100·1012-120·1012, cm3 - 25.0-30.0; 6% aluminium hydroxide, cm3 - 200.0-250.0; formalin, cm3 - 4.0-5.0; thermolabile and thermostable anatoxin of E.coli K99 and E.coli "ПЗ-3" strains in the ratio 1:1 in a culture medium with titre in "РДП" 1:8-1:16, l - to 1 l.
 Immunogenic composition for use in vaccination against staphylococci / 2419628
Invention relates to biotechnology. Immunogenic composition is described comprising an effective amount of a combination of at least two different proteins or their immunogenic fragments selected from at least two groups of proteins or immunogenic fragments selected from the following groups: group (a): at least one staphylococcal protein binding an extracellular component, or its immunogenic fragment; group (b): at least one staphylococcal transport protein or its immunogenic fragment; group (c): at least one staphylococcal regulator of virulence, toxin or its immunogenic fragment, wherein at least one protein or an immunogenic fragment is selected from the group (a), and at least one protein or immunogenic fragment is selected from the group (b). A vaccine against staphylococcal infection is proposed, which comprises an effective amount of the immunogenic composition described. Also the method to obtain the vaccine is offered.
Animal's pasteurellosis vaccine / 2414929
Invention refers to veterinary microbiology. A vaccine contains inactivated bacterial suspension Pasteurella multocida of serological versions A, B, D and an adjuvant. Additionally, the vaccine contains inactivated bacterial suspension Pasteurella haemolytica with activity of soluble surface antigens in passive hemagglutination test 1:32-64, and as an adjuvant - the adjuvant ISA-70VG in the following proportions, wt %: inactivated bacterial suspension Pasteurella multocida of serological versions A, B, D and inactivated bacterial suspension Pasteurella haemolytica taken in the mass ratios 1:(0.8-1.2):(0.8-1.2):(0.8-1.2) - 45-55, the adjuvant ISA-70VG - the rest.
Associated vaccine against streptococcosis and staphylococcosis of cattle / 2406533
Invention relates to veterinary medicine. Vaccine as antigens contains suspension of cells of pure cultures of causative agents of streptococcosis Streptococcus bovis and staphylococcosis Staphylococcus aureus, separated from local epizootic centre, glucose, formalin and aluminium hydroxide with the following component ratio, wt %: suspension of cells of pure culture of causative agent of streptococcosis Streptococcus bovis, separated from local epizootic centre, in nutrition medium with titre 4-5 billion microbial cells in 1 cm3 - 38.0-41.5, suspension of cells of pure culture of causative agent of staphylococcosis Staphylococcus aureus, separated from local epizootic centre, in nutrition medium with titre 4-5 billion microbial cells in 1 cm3 - 38.0-41.5, glucose - 2.0-1.0, formalin - 2.0-1.5, aluminium hydroxide - the remaining part.
Method of producing associated vaccine against streptococcosis and staphylococcosis of cattle / 2406532
Invention relates to field of veterinary medicine. Method lies in the following: carried out is selection of affected organs of dead cattle from local epizootic centre, from which suspension is prepared. After that, performed is inoculation on differential-diagnostic media and pure cultures are separated, and causative agents of streptococcosis Streptococcus bovis and staphylococcosis Staphylococcus aureus are grown separately in meat-peptone broth with addition of glucose to 0.2% concentration with titre 4-5 billion in 1 cm3. Cultures are inactivated by introduction of formalin to 0.4-0.5% final concentration and kept at temperature 37°C for 72-96 hours. After that, cultures are mixed in equal ratios, solution of aluminium hydroxide is introduced in amount 20% to the volume, thoroughly mixed and packed.
Method for producing diagnostic anthrax allergen / 2415941
Method provides recovery of a diagnostic anthrax allergen directly from a concentrated suspension of vegetative cells of a vaccine strain Bac. anthracis STI-1. The strain is grown on a nutrient medium based on a muriatic hydrolyzate of a fish flour by deep cultivation. The produced bacterial mass is washed in a separator to produce the concentrated suspension of vegetative cells. An allergenic protein fraction is recovered by alkaline hydrolysis, and the prepared hydrolyzate is fractioned. A protein allergen fraction is recovered from a supernatant of the recovered fraction by fractioning with an acetic acid solution; further the precipitation containing an end product is dissolved, dialyzed to produce a purified anthrax protein allergen. The preparation is presented in liquid and lyophilised forms.
Method for increase of melioidosis antigens protectivity by cytokines / 2376031
Invention is related to the field of medicine, in particular to microbiology and immunology and may be used in development of vaccine against melioidosis. Substance of method consists in the fact that animals are immunised with surface melioidosis complex, which consists of antigen 6 (AG6) and antigen d, which is injected to animals subcutaneously, twice, with interval of 10 days, in doses of 30 mcg by protein for mice or 150 mcg for rats. Simultaneously with primary immunisation recombinant interferon-γ - ingaron is injected in doses 8 ME for mice or 120 ME for rats, and in case of secondary immunisation, recombinant interleukin-2 - roncoleukin in doses of 0.6 mcg for mice or 10 mcg for rats, besides cytokines are injected to animals subcutaneously, daily, simultaneously with immunisation and in the next 2 days. In 21 days after primary immunisation animals are infected with 4-32 LD50 of highly virulent strain 100 of melioidosis causative agent, in 30 days after infection parametres of animal lethality are identified.
Method for immunoprophylaxis of experimental pseudocholera with entrapped antigens burkholderia pseudomallei / 2373955
Invention refers to medicine, particularly to microbiology and immunology and can be used for immunoprophylaxis of pseudocholera. The method involves antigen pretreatment to mice followed by infection and estimating level of protectivity. Antigens Burkholderia pseudomallei are chosen of superficial antigenic fractions: D, C, F, J, H. Herewith the antigen solution in amount 1.5 ml is mixed with phosphatidyl choline approximately 40 mg and cholesterol in the ratio 7:3 to produce liposomes.
Method of obtaining of anthracic protective antigen / 2340356
Plating of the vaccine strain on a sterile nutrient medium with sodium bicarbonate. Thus administer sodium bicarbonate into a nutrient medium throughout an exponential growth phase at 6-8 hours of the vaccine strain planting. After the planting process termination allocation, concentration and sterilisation of a protective antigen is performed on the equipment of ultra-and microstraining.
 Immunogenic composition (versions) based on recombinant intracellular pathogen / 2337707
Presented are immunogenic compositions including recombinant attenuated intracellular pathogens, e.g. Calmette-Guérin bacillus (CGB). Immunogenic composition specifically includes CGB containing sequenced extrachromosomal nucleic acid which includes gene coding large extracellular mycobacteria protein sized 23.5, 30 and/or 32 kDa, thus large extracellular unmerged mycobacteria protein is superexpressed and secreted. Version is immunogenic composition containing recombinant CGB with controlled growth. Introduction of immunogenic compositions in mammal organism is associated with superexpression and secretion of specified proteins causing immune response of organism to introduced antigene.
 Proteins causing alternated immunogenic response and methods for their preparing and using / 2311458
Invention relates to a variant of protein subtilysine from Bacillus amyloliquiefaciens with change Y217L and comprising T-cellular epitope. This T-cellular epitope of indicated variant comprises one or some amino acid changes chosen from group consisting of residues corresponding to positions: 76, 79 and 122 wherein indicated subtilysine variant has optionally change at one or some following positions: 3, 31, 40, 41, 46, 47, 48, 50, 76, 101, 104, 107, 111, 128, 147, 154, 181, 182, 183, 185, 206, 215, 218, 238, 247, 248, 250, 254, 258 and 262. Also, invention relates to DNA molecules that encode subtilysine variants, host-cells containing this DNA, and to compositions used in skin care and containing indicated subtilysine variants. Invention provides preparing subtilysine variants that elicit reduced immunogenic response in human as compared with the parent subtilysine.
 Method for preparing nontoxic anti-anthrax vaccine / 2287581
Invention relates to producing vaccines and describes anti-anthrax vaccine that comprises mutant protein toxin from Bacillus anthracis chosen from mutant PA or mutant LF, or mutant EF or their combinations. Mutations of toxins provide the retained immunogenicity in decreasing the level of their toxicity. For the development of vaccine with reduced reactivity invention proposes recombinant DNA-construction for expression of said protein-toxins. DNA-construction comprises the expressing vector and DNA fragment comprising, in turn, genes encoding the corresponding protein-toxin (PA, LF or EF). Invention describes a method for preparing mutant proteins by using the transformed prokaryotic host. Prepared mutant protein-toxin possessing immunogenic properties and absence of toxicity is used for preparing anti-anthrax vaccine comprising one or more mutant protein-toxins and in combination with protein-toxin PA, LF or EF of wild type. Using the invention provides to develop the safety and effective vaccine against anthrax.
Associated vaccine against anthrax and plague in cattle / 2286173
The suggested vaccine contains suspension of viable spores of anthracic vaccinal strain "55-VNIIBB&M" at initial concentration of 500-700 mln. spores/cu.cm, cultural virus-containing raw material of vaccinal virus of cattle plague of "LT" strain at activity of not less than 7.0 lg TCD50/cu. cm, lactosopeptonic stabilizing agent and distilled water at the following content of components,%: spores of anthracic strain "55-VNIIVV&M" -6.2 - 10.0; cultural raw material of cattle plague virus of "LT" strain -25.0 - 30.0; lactosopeptonic stabilizing agent -48.0 - 50.0; distilled water - the rest. One vaccinal dosage contains about 20-25 mln. anthracic spores and about 4.5-5.5 lg TCD50 of cattle plague virus The suggested vaccine is of high immunogenicity, develops tense immunity in once vaccinated cattle that lasts for 12 mo, not less, moreover, it is areactogenous, safe and stable at storage.
 Immunogenic polypeptide inducing protective immune response against bacillus anthracis (variants), method for its preparing, nucleic acid encoding thereof, expression vector (variants), method and vaccine for prophylaxis of infection caused by bacillus anthracis / 2270865
Invention relates to a method for preparing an immunogenic polypeptide inducing immune response that represents the protective response against infection with Bacillus anthracis. Proposed immunogenic polypeptide comprises from one to three domains of the full-scale Protective Antigen (PA) from B. anthracis or their variants and at least one of indicated domains represents domain 1 or domain 4 from PA or its variant. These variants of immunogenic polypeptide and full-scale PA are produced as result of expression in E. coli. Also, invention proposes a vector for expression in bacterial cells that comprises nucleic acid encoding abovementioned immunogenic polypeptide. Also, invention the developed method for prophylaxis of infection caused by B. anthracis based on administration of sufficient amount of immunogenic polypeptide. Also, invention proposes a vaccine for prophylaxis of infection caused by B. anthracis that comprises the effective amount of immunogenic polypeptide and a suitable carrier. Invention provides preparing the effective agent used for prophylaxis of infection caused by B. anthracis.
 Method for production of immune serum to virulent strain bacillus anthracis antigen / 2252031
Claimed method includes administering before contamination to the animal subsequently in right pope then after 14 days in left pope 0.2 ml of non-complete Freund's adjuvant with equal volume of physiological salt solution. Subsequent administering after 14 days in right pope up to 10 LD50 of Bacillus anthracis 81/1 spore dredge doesn't cause animal death for long period (monitoring time is 35 days).
Method for production of immune serum to virulent strain bacillus anthracis antigen / 2252031
Claimed method includes administering before contamination to the animal subsequently in right pope then after 14 days in left pope 0.2 ml of non-complete Freund's adjuvant with equal volume of physiological salt solution. Subsequent administering after 14 days in right pope up to 10 LD50 of Bacillus anthracis 81/1 spore dredge doesn't cause animal death for long period (monitoring time is 35 days).
|
FIELD: medicine, pharmaceutics. SUBSTANCE: invention refers to veterinary science and biotechnology, and concerns preparing an associated vaccines for prevention of anthrax and necrobacillosis in animals. The characterized vaccine contains the following ingredients in proportions, wt %: a suspension of living spores of the anthrax vaccine strain 55-VNIIVViM (All-Russian Research Institution of Virology and Microbiology) with the initial concentration of (5-5.2)X107 in physiologic saline 1 cm3 - 1.0-1.2; -saponin - 1.5-2.1; -formalin-inactivated leukocidin - exotoxin with molecular weight 18-20 kDa of the strain of Fusobacterium necrophorum "0-1" VIEV (All-Russian Institution of Experimental Virology with the protein content of 5.5- 6 mg % adsorbed in 12-15% aluminium hydroxide taken in the final concentration of 1.8-2.0% pre-suspended in glycol buffer with pH 8.4-8.6 - the rest. EFFECT: preparing high-immunogenic product providing the formation of prolonged and expressed anthrax and necrobacillosis immunity. 2 tbl, 3 ex
The invention relates to the field of veterinary medicine and biotechnology and the receipt of the associated vaccine to prevent anthrax and nitrobacteria animals. Known vaccine for the prevention of microbacteria cattle containing equal volume ratios formalin inactivated endotoxin and exotoxin derived from local epizootic cultures of the pathogen microbacteria, and adjuvant on the basis of mineral oil and lanolin (Patent RU 1816348, IPC A61K 39/00, 1995). However, the known vaccine is not enough immunogen, as it requires a double injection and provides immunity only against microbacteria for 3.5-4 months. In addition, when receiving vaccines carry out a preliminary selection of local strains for each specific sector, which is not possible in industrial production. Known vaccine against anthrax in animals, containing a suspension of live spores paskapallero, avirulent vaccine strain 55-Vniivvim anthrax (THE 9388-004-00008064-99). Known also inactivated vaccine microbacteria animals containing formalin inactivated endotoxin and exotoxin derived from the production strain "0-1" VIEW pathogen microbacteria, and adjuvant on the basis of mineral oil and lanolin (Patent RU 210519, IPC A61K 39/02, A61K 39/114, 1998). Existing single used independently of each other and do not create immunity in animals against anthrax and nitrobacteria. The use of these vaccines separately requires twice the amount of work and has a strong stress animals. Known associated vaccine against anthrax and nitrobacteria containing an inactivated by formalin-leukocidin-exotoxin that results from the production of strains of Fusobacterium necrophorum "0-1" VIEW, representing a highly purified protein with a molecular mass of 18-20 kDa and adsorbed on aluminium hydroxide, and the suspension of live spores of the anthrax vaccine strain 55-Vniivvim in physiological solution, and adjuvant (Patent RU №2191599, 2002). However, the known associated vaccine does not provide a sufficient immunity against anthrax and nitrobacteria. The objective of the invention is to improve the quality of the target product by obtaining highly immunogenic vaccine capable of forming a long and busy immunity against anthrax and nitrobacteria. The technical result of the invention is achieved in the associated vaccine against anthrax and nitrobacteria containing an inactivated formal is the nom leukocidin-exotoxin, results from the production of strains of Fusobacterium necrophorum "0-1" VIEW, representing a highly purified protein with a molecular mass of 18-20 kDa and adsorbed on aluminium hydroxide, and the suspension of live spores of the anthrax vaccine strain 55-Vniivvim in physiological solution, and adjuvant fact that formalin inactivated leukocidin-exotoxin adsorbed 12-15% aluminum hydroxide in picokelvin buffer with a pH of 8.4 and 8.6, taken at a final concentration of 1.8-2.0%, the suspension of live spores of the anthrax vaccine strain 55-Vniivvim use with the original concentration (5-5,2)×1071 cm3saline and adjuvant contains saponin in the following ratio, wt.%:
Associated vaccine is administered once cattle, sheep, goats, pigs and the reindeers intradermally using a needleless injector in the amount of 0.2 cm3. Saponin-glucoside, determining specific properties of the so-called. soap root. The chemical composition, Rohleder, C32H54O18; /Lyzer, Mfisher. Organic chemistry. Volume II. M. Chemistry, 1970. - s/. Proposed associated vaccine against anthrax and nitrobacteria that creates long-lasting immunity in vaccinated animals simultaneously against two diseases, while on the immunogenicity of it than the known vaccine against anthrax and nitrobacteria through the use of not only as an adjuvant saponin, and found the optimum ratio of the adsorbent leukocidin-exotoxin - aluminium hydroxide in specific technological conditions. Also the decrease in the concentration of live spores of the anthrax vaccine strain hundreds of times in comparison with the known technical solution reduces the reactogenicity of the target product. The invention is illustrated by the following examples. Example 1. Associated vaccinated anthrax and nitrobacteria prepared as follows. To obtain microbacterial antigen - leukocidin-exotoxin take production strain Fusobacterium necrophorum "0-1" VIEW, cultivate, inactivate formalin at a final concentration of 0.4%, separating backass from the culture fluid by centrifugation from the culture fluid secrete an exotoxin which is subjected to high purification by ultrafiltration in hollow fibers with a pore size 13-17 kDa and concentrated to a protein content (Lowry) to 5.5 mg% with a molecular mass of 18-20 kDa. Next, the resulting antigen - leukocidin-exotoxin absorb 12% aluminium hydroxide, taken at a final concentration of 1.8%, previously suspended in picokelvin buffer with a pH of 8.4. After adsorption of the antigen on the hydrate of alumina check the neutralization of the residual formalin. To 97.5 g of inaktivirovannaja formalin leukocidin-exotoxin with mm 18-20 kDa from strains of Fusobacterium necrophorum "0-1" VIEW protein content of 5.5 mg%adsorbed 12% aluminum hydroxide, taken at a final concentration of 1.8%, previously suspended in picokelvin buffer with a pH of 8.4, add 1.0 g of a suspension of live spores of the anthrax vaccine strain 55-Vniivvim with the initial concentration of 5.0×1071 cm3saline solution and 1.5 g of saponin, receiving structure 1 in the following ratio, wt.%:
The vaccine is thoroughly mixed until a homogeneous suspension. Example 2. Associated vaccine against anthrax and nitrobacteria prepared as follows. To obtain microbacterial antigen - leukocidin-exotoxin take production strain Fusobacterium necrophorum "0-1" VIEW, cultivate, inactivate formalin at a final concentration of 0.5%, separating backass from the culture fluid by centrifugation from the culture fluid secrete an exotoxin which is subjected to high purification by ultrafiltration in hollow fibers with a pore size of 13 to 17 is Yes, and concentrated to a protein content (Lowry) 6.0 mg% with a molecular mass of 18-20 kDa. Next, the resulting antigen - leukocidin-exotoxin absorb 15% aluminum hydroxide, taken at a final concentration of 2.0%, previously suspended in picokelvin buffer with a pH of 8.6. After adsorption of the antigen on the hydrate of alumina check the neutralization of the residual formalin. To 96,7 g inaktivirovannaja formalin leukocidin-exotoxin with mm 18-20 kDa from strains of Fusobacterium necrophorum "0-1" VIEW a protein content of 6 mg%adsorbed 15% aluminum hydroxide, taken at a final concentration of 2.0%, previously suspended in picokelvin buffer with a pH of 8.6, add 1.2 g of a suspension of live spores of the anthrax vaccine strain 55-Vniivvim with the initial concentration of 5.2×1071 cm3saline solution and 2.1 g of saponin, receiving part 2 in the following ratio, wt.%:
The vaccine is thoroughly mixed until a homogeneous suspension. Example 3. Obtained according to examples 1 and 2, as well as the prototype associated vaccine against anthrax and nitrobacteria used for preventive and forced vaccinations clinically healthy animals. Calves under 3 months of age, instill the associated vaccine is not permitted. The vaccine is administered intradermally using a needleless injector in hairless area of the body animals 0.2 cm3(2 times in 0.1 cm3): Guinea pigs, sheep and the reindeers. The test results are known and the proposed associated vaccines against anthrax and nitrobacteria presented in tables 1 and 2. Thus, the associated vaccine against anthrax and nitrobacteria has a higher immunogenic activity, able to protect animals against anthrax and nitrobacteria /extends immunity from one year to 1.5 years for the prevention of Siberian ulcer and with six months to 1.5 years to prevent microbacteria/. td align="center"> sheep
The associated vaccine against anthrax and nitrobacteria containing an inactivated by formalin-leukocidin-exotoxin, obtained from the production strain Fusobactcrium nccrophorum "0-1" VIEW, representing a highly purified protein with a molecular mass of 18-20 kDa and adsorbed on aluminium hydroxide, and the suspension of live spores of the anthrax vaccine strain 55-Vniivvim in physiological solution, and adjuvant, wherein an inactivated by formalin-leukocidin-exotoxin adsorbed 12-15%aluminum hydroxide, taken at a final concentration of 1.8-2.0%, previously suspended in picokelvin buffer with a pH of 8.4 and 8.6, the suspension of live spores anthrax vaccine strain 55-Vniivvim use with the original concentration (5-5,2)·1071 cm3saline and adjuvant contains saponin in the following ratio, wt.%:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||